Your browser doesn't support javascript.
loading
Assessment of Enterovirus Excretion and Identification of VDPVs in Patients with Primary Immunodeficiency in India: Outcome of ICMR-WHO Collaborative Study Phase-I.
Mohanty, Madhu Chhanda; Desai, Mukesh; Mohammad, Ahmad; Aggarwal, Amita; Govindaraj, Geeta; Bhattad, Sagar; Lashkari, Harsha Prasada; Rajasekhar, Liza; Verma, Harish; Kumar, Arun; Sawant, Unnati; Varose, Swapnil Yashwant; Taur, Prasad; Yadav, Reetika Malik; Tatkare, Manogat; Fernandes, Mevis; Bargir, Umair; Majumdar, Sanjukta; Edavazhippurath, Athulya; Rangarajan, Jyoti; Manthri, Ramesh; Madkaikar, Manisha Ranjan.
Afiliação
  • Mohanty MC; Mumbai Unit, ICMR-National Institute of Virology (ICMR-NIV), Mumbai 400012, India.
  • Desai M; Department of Immunology, Bai Jerbai Wadia Hospital for Children, Mumbai 400012, India.
  • Mohammad A; World Health Organization, Country Office, New Delhi 110011, India.
  • Aggarwal A; Department of Clinical Immunology & Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India.
  • Govindaraj G; Department of Pediatrics, Government Medical College, Kozhikode 673008, India.
  • Bhattad S; Department of Pediatrics, Aster CMI Hospital, Bangalore 560092, India.
  • Lashkari HP; Department of Pediatrics, Kasturba Medical College, Mangalore 576104, India.
  • Rajasekhar L; Department of Clinical Immunology and Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad 500082, India.
  • Verma H; World Health Organization, CH-1211 Geneva, Switzerland.
  • Kumar A; World Health Organization, Country Office, New Delhi 110011, India.
  • Sawant U; Mumbai Unit, ICMR-National Institute of Virology (ICMR-NIV), Mumbai 400012, India.
  • Varose SY; Mumbai Unit, ICMR-National Institute of Virology (ICMR-NIV), Mumbai 400012, India.
  • Taur P; Department of Immunology, Bai Jerbai Wadia Hospital for Children, Mumbai 400012, India.
  • Yadav RM; ICMR-National Institute of Immunohaematology (ICMR-NIIH), Mumbai 400012, India.
  • Tatkare M; Mumbai Unit, ICMR-National Institute of Virology (ICMR-NIV), Mumbai 400012, India.
  • Fernandes M; Mumbai Unit, ICMR-National Institute of Virology (ICMR-NIV), Mumbai 400012, India.
  • Bargir U; ICMR-National Institute of Immunohaematology (ICMR-NIIH), Mumbai 400012, India.
  • Majumdar S; Department of Clinical Immunology & Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India.
  • Edavazhippurath A; Multidisciplinary Research Unit, Government Medical College, Kozhikode 673008, India.
  • Rangarajan J; Department of Pediatrics, Aster CMI Hospital, Bangalore 560092, India.
  • Manthri R; Department of Clinical Immunology and Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad 500082, India.
  • Madkaikar MR; ICMR-National Institute of Immunohaematology (ICMR-NIIH), Mumbai 400012, India.
Vaccines (Basel) ; 11(7)2023 Jul 06.
Article em En | MEDLINE | ID: mdl-37515027
The emergence of vaccine-derived polioviruses (VDPVs) in patients with Primary Immunodeficiency (PID) is a threat to the polio-eradication program. In a first of its kind pilot study for successful screening and identification of VDPV excretion among patients with PID in India, enteroviruses were assessed in stool specimens of 154 PID patients across India in a period of two years. A total of 21.42% of patients were tested positive for enteroviruses, 2.59% tested positive for polioviruses (PV), whereas 18.83% of patients were positive for non-polio enteroviruses (NPEV). A male child of 3 years and 6 months of age diagnosed with Hyper IgM syndrome was detected positive for type1 VDPV (iVDPV1) with 1.6% nucleotide divergence from the parent Sabin strain. E21 (19.4%), E14 (9%), E11 (9%), E16 (7.5%), and CVA2 (7.5%) were the five most frequently observed NPEV types in PID patients. Patients with combined immunodeficiency were at a higher risk for enterovirus infection as compared to antibody deficiency. The high susceptibility of PID patients to enterovirus infection emphasizes the need for enhanced surveillance of these patients until the use of OPV is stopped. The expansion of PID surveillance and integration with a national program will facilitate early detection and follow-up of iVDPV excretion to mitigate the risk for iVDPV spread.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Índia

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Índia